News

Weekly Policy Update: Drug Pricing Transparency Bill Introduced in Colorado, Plus CBSA Advocates in DC

Friday, April 05, 2019

 

CBSA and BIO Honor Colorado Congressional Leaders as Innovators in Biotechnology

Thursday, April 04, 2019

Senator Michael Bennet, Congresswoman Diana DeGette Recognized as Champions of Life Science 
Continue Reading

Colorado BioScience Association Applauds Expansion by Novartis Company AveXis to Longmont

Monday, April 01, 2019

April 1, 2019
 

Weekly Policy Update: CBSA Raises Concerns about Importing Drugs From Canada, Plus A Full Review of this Month In Policy

Friday, March 29, 2019

This week President & CEO Jennifer Jones Paton spoke with 630 KHOW’s Krista Kafer about CBSA’s opposition to Senate Bill 5, which would create a Canadian drug importation program in Colorado. Throughout the conversation Jennifer explained that the innovators CBSA represents are dedicated to developing new treatments and cures and ensuring patients have access to those medicines, but this legislation would jeopardize patient safety and do little to reduce prescription drug costs.  

Weekly Policy Update: Colorado State Budget and Forecast, Plus CBSA Voices Concerns on Drug Pricing Legislation

Friday, March 22, 2019

 

Weekly Policy Update: Family Medical Leave Insurance Program and the President's Proposed Budget

Friday, March 15, 2019

On Wednesday Senate Bill 188, FAMLI Family Medical Leave Insurance Program, was heard and passed out of the Senate Committee on Business, Labor & Technology. The bill would create a state-run family and medical leave insurance program to provide partial wage replacement benefits to an eligible individual who takes leave from work:  

Weekly Policy Update: Colorado BioScience Association’s Annual Day at the Capitol

Friday, March 08, 2019

 

Colorado BioScience Association Explores New Possibilities for Medtech at Annual Symposium

Monday, March 04, 2019

Medical device industry leaders to focus on blockchain technology, M&A trends and federal policy 
Continue Reading

David Perez Is Leaving Terumo BCT, But He'll Still Be Active In The Bioscience Community

Friday, March 01, 2019

Terumo BCT's CEO David Perez may be retiring, but he isn't leaving the Colorado bioscience community. He sat down with the Denver Business Journal’s James Rodriguez to discuss his successes at Terumo BCT and offer his thoughts on the larger Colorado bioscience community.  

Weekly Policy Update: AdvaMed Fly-In and the Monthly Report

Friday, March 01, 2019